Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter), Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)
The vascular disrupting agents market is expected to reach USD 23 million in 2021 and anticipated to grow at a CAGR of 65% during the forecast period 2021-2030.
Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts towards developing innovative anticancer therapies tailored for these types of cancers. Over the past five years, the United States Food and Drug Administration (USFDA) has approved over 100 drugs for diverse cancer treatments. Despite these advancements, the increasing global exposure to various carcinogens and risk factors necessitates the development of more targeted and potent drugs or therapies to effectively combat this complex and life-threatening disease. The rapid growth of malignant cell masses that characterize solid tumors emphasizes the critical role of angiogenesis and adequate blood supply in sustaining the tumor population. Consequently, targeting tumor vasculature remains a compelling and promising approach in therapeutic pursuits. Vascular disrupting agents (VDAs) are interventions aimed at established tumor vasculature, thereby disrupting blood flow to cancerous tissues.
Currently, several small molecule VDAs are either under development or have been developed to address various oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma, and ovarian cancer. Additionally, combination therapies that integrate VDAs with conventional chemotherapy, radiation therapy, and radioimmunotherapy have shown significant clinical responses in various animal models.
Significantly, the advancements in this field receive substantial support from the National Institutes of Health, with research grants totaling USD 95 million disbursed since 2016. Driven by promising clinical research outcomes, this specialized yet burgeoning domain is poised for robust market growth in the foreseeable future. Early entrants are expected to gain a competitive edge as pioneers in this evolving landscape.
Report Coverage
Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts towards developing innovative anticancer therapies tailored for these types of cancers. Over the past five years, the United States Food and Drug Administration (USFDA) has approved over 100 drugs for diverse cancer treatments. Despite these advancements, the increasing global exposure to various carcinogens and risk factors necessitates the development of more targeted and potent drugs or therapies to effectively combat this complex and life-threatening disease. The rapid growth of malignant cell masses that characterize solid tumors emphasizes the critical role of angiogenesis and adequate blood supply in sustaining the tumor population. Consequently, targeting tumor vasculature remains a compelling and promising approach in therapeutic pursuits. Vascular disrupting agents (VDAs) are interventions aimed at established tumor vasculature, thereby disrupting blood flow to cancerous tissues.
Currently, several small molecule VDAs are either under development or have been developed to address various oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma, and ovarian cancer. Additionally, combination therapies that integrate VDAs with conventional chemotherapy, radiation therapy, and radioimmunotherapy have shown significant clinical responses in various animal models.
Significantly, the advancements in this field receive substantial support from the National Institutes of Health, with research grants totaling USD 95 million disbursed since 2016. Driven by promising clinical research outcomes, this specialized yet burgeoning domain is poised for robust market growth in the foreseeable future. Early entrants are expected to gain a competitive edge as pioneers in this evolving landscape.
Report Coverage
- Examine the vascular disrupting agents market by categorizing it based on indications, therapeutic areas, molecules, therapy types, administration routes, and geographical regions.
- Analyze market growth factors like drivers, restraints, opportunities, and challenges.
- Evaluate potential market advantages and obstacles, focusing on the competitive landscape for leading players.
- Forecast revenue for market segments across six major regions.
- Assess the current landscape of vascular disrupting agents, detailing developmental stages of product candidates, therapeutic areas, molecule types, therapy types, and administration routes. Provide a comprehensive list of companies involved in this development, considering establishment year, company size, and headquarters location.
- Present detailed profiles of prominent market players based on their pipeline volume, including company overview, financial information, lead drug candidates' descriptions, development status, indications, mode of action, therapy type, recent developments, and future forecasts.
- Conduct an in-depth analysis of completed, ongoing, and planned clinical studies on vascular disrupting agents. Highlight trends in trial status, patient population, regional distribution, molecule types, developmental phases, study designs, leading industry and non-industry players, focus, and key indications.
- Review over 750 peer-reviewed scientific articles on vascular disrupting agents published between 2016 and January 2021. Analyze trends in publication years, emerging focus areas, keywords, indications, therapeutic areas, research journals, and notable authors.
- Analyze grants awarded to research institutes between 2016 and January 2021 related to vascular disrupting agents. Parameters include the year of award, amount, administering institute, support period, grant type, purpose, activity code, focus areas, popular departments, recipient organization types, highlighting popular recipients, program officers, and regional distribution.
- Compile a list of key opinion leaders (KOLs) in the vascular disrupting agents market. Assess their prominence and activity using a 2x2 matrix representation. Create a world map indicating the locations of eminent scientists/researchers. Evaluate KOL expertise based on publications, citations, clinical trial participation, affiliations, and professional networks available on ResearchGate.
- AGC Biologics
- Avid Bioservices
- Bionomics
- Mateon Therapeutics
- Myrexis
- VBL Therapeutics
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Vascular Disrupting Agents
3.2.1. Mechanism of Action of Vascular Disrupting Agents
3.3 Types of Vascular Disrupting Agents
3.3.1. Small Molecule Vascular Disrupting Agents
3.3.1.1. Tubulin Binding Agents
3.3.1.2. Flavonoids
3.3.2. Ligand Directed Vascular Disrupting Agents
3.4. Benefits of Vascular Disrupting Agents
3.5. Challenges Associated with Vascular Disrupting Agents
3.6. Future Perspectives
4. VASCULAR DISRUPTING AGENTS MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vascular Disrupting Agents: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Target Disease Indication
4.2.4. Analysis by Phase of Development and Target Disease Indication
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Target Disease Indication and Type of Molecule
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Potential Combination Therapeutics
4.3. Vascular Disrupting Agents: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Drug Candidates
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Company Overview
5.2.2. Drug Portfolio: Vascular Disrupting Agents
5.2.2.1. Drug Profile: NGR-TNF
5.2.3. Recent Developments and Future Outlook
5.3. Avid Bioservices
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio: Vascular Disrupting Agents
5.3.3.1. Drug Profile: Bavituximab
5.3.4. Recent Developments and Future Outlook
5.4. Bionomics
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Drug Portfolio: Vascular Disrupting Agents
5.4.3.1. Drug Profile: BNC105
5.4.4. Recent Developments and Future Outlook
5.5. Mateon Therapeutics
5.5.1. Company Overview
5.5.2. Drug Portfolio: Vascular Disrupting Agents
5.5.2.1. Drug Profile: CA4P
5.5.2.2. Drug Profile: OXi4503
5.5.3. Recent Developments and Future Outlook
5.6. Myrexis
5.6.1. Company Overview
5.6.2. Drug Portfolio: Vascular Disrupting Agents
5.6.2.1. Drug Profile: MPC-6827
5.6.3. Recent Developments and Future Outlook
5.7. VBL Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Drug Portfolio: Vascular Disrupting Agents
5.7.3.1. Drug Profile: VB-111
5.7.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Vascular Disrupting Agents: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Trial Status
6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.4. Analysis by Trial Phase
6.3.5. Analysis by Trial Phase and Number of Patients Enrolled
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Geographical Analysis by Number of Patients Enrolled
6.3.8. Analysis by Study Design
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Drug Molecule
6.3.11. Analysis by Key Indications
6.3.12. Analysis by Type of Sponsor / Collaborator
6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Vascular Disrupting Agents: List of Recent Publications
7.3.1. Analysis by Year of Publication
7.3.2. Emerging Focus Areas
7.3.3. Analysis by Popular Keywords
7.3.4. Analysis by Target Disease Indications
7.3.5. Analysis by Therapeutic Area
7.3.6. Popular Journals: Analysis by Number of Publications
7.3.7. Popular Journals: Analysis of Journal Impact Factor
7.3.8. Most Popular Authors: Analysis by Number of Publications
8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Vascular Disrupting agents: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Activity Code
8.3.8. Word Cloud Analysis: Emerging Focus Areas
8.3.9. Popular Recipient Organizations: Analysis by Number of Grants
8.3.10. Prominent Program Officers: Analysis by Number of Grants
8.3.11. Regional Distribution of Recipient Organizations
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Methodology
9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials
9.3.1. Geographical Distribution of KOLs
9.3.2. Analysis by Type of Organization (KOL Affiliation)
9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
9.4. Prominent Key Opinion Leaders (KOLs)
9.5. KOL Benchmarking: Roots Analysis versus Third-Party Scoring (ResearchGate Score)
9.6. Profiles of Most Active KOLs
9.6.1. KOL Profile: KOL A
9.6.2. KOL Profile: KOL B
9.6.3. KOL Profile: KOL C
9.6.4. KOL Profile: KOL D
9.6.5. KOL Profile: KOL E
9.6.6. KOL Profile: KOL F
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall Vascular Disrupting Agents Market, 2021-2030
10.4.1. Vascular Disrupting Agents Market: Distribution by Target Indication
10.4.2. Vascular Disrupting Agents Market: Distribution by Therapeutic Area
10.4.3. Vascular Disrupting Agents Market: Distribution by Type of Molecule
10.4.4. Vascular Disrupting Agents Market: Distribution by Type of Therapy
10.4.5. Vascular Disrupting Agents Market: Distribution by Route of Administration
10.4.6. Vascular Disrupting Agents Market: Distribution by Geography
10.4.7. Product-wise Sales Forecast
10.4.7.1. Bavituximab (Avid Bioservices)
10.4.7.1.1. Target Patient Population
10.4.7.1.2. Sales Forecast (USD Million)
10.4.7.1.3. Net Present Value (USD Million)
10.4.7.1.4. Value Creation Analysis
10.4.7.2. Icaritin (Beijing Shenogen Biomedical)
10.4.7.2.1. Target Patient Population
10.4.7.2.2. Sales Forecast (USD Million)
10.4.7.2.3. Net Present Value (USD Million)
10.4.7.2.4. Value Creation Analysis
10.4.7.3. NGR-TNF (AGC Biologics)
10.4.7.3.1. Target Patient Population
10.4.7.3.2. Sales Forecast (USD Million)
10.4.7.3.3. Net Present Value (USD Million)
10.4.7.3.4. Value Creation Analysis
10.4.7.4. Padeliporfin (Steba biotech)
10.4.7.4.1. Target Patient Population
10.4.7.4.2. Sales Forecast (USD Million)
10.4.7.4.3. Net Present Value (USD Million)
10.4.7.4.4. Value Creation Analysis
10.4.7.5. Plinabulin (BeyondSpring Pharmaceuticals)
10.4.7.5.1. Target Patient Population
10.4.7.5.2. Sales Forecast (USD Million)
10.4.7.5.3. Net Present Value (USD Million)
10.4.7.5.4. Value Creation Analysis
10.4.7.6. VB-111 (VBL Therapeutics)
10.4.7.6.1. Target Patient Population
10.4.7.6.2. Sales Forecast (USD Million)
10.4.7.6.3. Net Present Value (USD Million)
10.4.7.6.4. Value Creation Analysis
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Vascular Disrupting Agents
3.2.1. Mechanism of Action of Vascular Disrupting Agents
3.3 Types of Vascular Disrupting Agents
3.3.1. Small Molecule Vascular Disrupting Agents
3.3.1.1. Tubulin Binding Agents
3.3.1.2. Flavonoids
3.3.2. Ligand Directed Vascular Disrupting Agents
3.4. Benefits of Vascular Disrupting Agents
3.5. Challenges Associated with Vascular Disrupting Agents
3.6. Future Perspectives
4. VASCULAR DISRUPTING AGENTS MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vascular Disrupting Agents: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Target Disease Indication
4.2.4. Analysis by Phase of Development and Target Disease Indication
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Target Disease Indication and Type of Molecule
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Potential Combination Therapeutics
4.3. Vascular Disrupting Agents: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Drug Candidates
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Company Overview
5.2.2. Drug Portfolio: Vascular Disrupting Agents
5.2.2.1. Drug Profile: NGR-TNF
5.2.3. Recent Developments and Future Outlook
5.3. Avid Bioservices
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio: Vascular Disrupting Agents
5.3.3.1. Drug Profile: Bavituximab
5.3.4. Recent Developments and Future Outlook
5.4. Bionomics
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Drug Portfolio: Vascular Disrupting Agents
5.4.3.1. Drug Profile: BNC105
5.4.4. Recent Developments and Future Outlook
5.5. Mateon Therapeutics
5.5.1. Company Overview
5.5.2. Drug Portfolio: Vascular Disrupting Agents
5.5.2.1. Drug Profile: CA4P
5.5.2.2. Drug Profile: OXi4503
5.5.3. Recent Developments and Future Outlook
5.6. Myrexis
5.6.1. Company Overview
5.6.2. Drug Portfolio: Vascular Disrupting Agents
5.6.2.1. Drug Profile: MPC-6827
5.6.3. Recent Developments and Future Outlook
5.7. VBL Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Drug Portfolio: Vascular Disrupting Agents
5.7.3.1. Drug Profile: VB-111
5.7.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Vascular Disrupting Agents: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Trial Status
6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.4. Analysis by Trial Phase
6.3.5. Analysis by Trial Phase and Number of Patients Enrolled
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Geographical Analysis by Number of Patients Enrolled
6.3.8. Analysis by Study Design
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Drug Molecule
6.3.11. Analysis by Key Indications
6.3.12. Analysis by Type of Sponsor / Collaborator
6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Vascular Disrupting Agents: List of Recent Publications
7.3.1. Analysis by Year of Publication
7.3.2. Emerging Focus Areas
7.3.3. Analysis by Popular Keywords
7.3.4. Analysis by Target Disease Indications
7.3.5. Analysis by Therapeutic Area
7.3.6. Popular Journals: Analysis by Number of Publications
7.3.7. Popular Journals: Analysis of Journal Impact Factor
7.3.8. Most Popular Authors: Analysis by Number of Publications
8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Vascular Disrupting agents: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Activity Code
8.3.8. Word Cloud Analysis: Emerging Focus Areas
8.3.9. Popular Recipient Organizations: Analysis by Number of Grants
8.3.10. Prominent Program Officers: Analysis by Number of Grants
8.3.11. Regional Distribution of Recipient Organizations
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Methodology
9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials
9.3.1. Geographical Distribution of KOLs
9.3.2. Analysis by Type of Organization (KOL Affiliation)
9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
9.4. Prominent Key Opinion Leaders (KOLs)
9.5. KOL Benchmarking: Roots Analysis versus Third-Party Scoring (ResearchGate Score)
9.6. Profiles of Most Active KOLs
9.6.1. KOL Profile: KOL A
9.6.2. KOL Profile: KOL B
9.6.3. KOL Profile: KOL C
9.6.4. KOL Profile: KOL D
9.6.5. KOL Profile: KOL E
9.6.6. KOL Profile: KOL F
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall Vascular Disrupting Agents Market, 2021-2030
10.4.1. Vascular Disrupting Agents Market: Distribution by Target Indication
10.4.2. Vascular Disrupting Agents Market: Distribution by Therapeutic Area
10.4.3. Vascular Disrupting Agents Market: Distribution by Type of Molecule
10.4.4. Vascular Disrupting Agents Market: Distribution by Type of Therapy
10.4.5. Vascular Disrupting Agents Market: Distribution by Route of Administration
10.4.6. Vascular Disrupting Agents Market: Distribution by Geography
10.4.7. Product-wise Sales Forecast
10.4.7.1. Bavituximab (Avid Bioservices)
10.4.7.1.1. Target Patient Population
10.4.7.1.2. Sales Forecast (USD Million)
10.4.7.1.3. Net Present Value (USD Million)
10.4.7.1.4. Value Creation Analysis
10.4.7.2. Icaritin (Beijing Shenogen Biomedical)
10.4.7.2.1. Target Patient Population
10.4.7.2.2. Sales Forecast (USD Million)
10.4.7.2.3. Net Present Value (USD Million)
10.4.7.2.4. Value Creation Analysis
10.4.7.3. NGR-TNF (AGC Biologics)
10.4.7.3.1. Target Patient Population
10.4.7.3.2. Sales Forecast (USD Million)
10.4.7.3.3. Net Present Value (USD Million)
10.4.7.3.4. Value Creation Analysis
10.4.7.4. Padeliporfin (Steba biotech)
10.4.7.4.1. Target Patient Population
10.4.7.4.2. Sales Forecast (USD Million)
10.4.7.4.3. Net Present Value (USD Million)
10.4.7.4.4. Value Creation Analysis
10.4.7.5. Plinabulin (BeyondSpring Pharmaceuticals)
10.4.7.5.1. Target Patient Population
10.4.7.5.2. Sales Forecast (USD Million)
10.4.7.5.3. Net Present Value (USD Million)
10.4.7.5.4. Value Creation Analysis
10.4.7.6. VB-111 (VBL Therapeutics)
10.4.7.6.1. Target Patient Population
10.4.7.6.2. Sales Forecast (USD Million)
10.4.7.6.3. Net Present Value (USD Million)
10.4.7.6.4. Value Creation Analysis
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
